Remarkable selectivity of the in vivo binding of [3H]Ro15-4513 to α5 subtype of benzodiazepine receptor in the living mouse brain

Sotaro Momosaki, Rie Hosoi, Koji Abe, Osamu Inoue

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

To evaluate the binding characteristics of [3H]Ro15-4513 with the central benzodiazepine (BZ) receptor, inhibition experiments of [3H]Ro15-1788 and [3H]Ro15-4513 were performed both in vitro and in vivo, using two BZ ligands, flunitrazepam (FNP), and ethyl-β-carboline-3-carboxylate (β-CCE). FNP inhibited the binding of [3H]Ro15-1788 and [3H]Ro15-4513 in a dose-dependent manner in the mouse cerebral cortex, hippocampus, and cerebellum, both in vitro and in vivo. β-CCE also inhibited the binding of [3H]Ro15-1788 and [3H]Ro15-4513 in all the aforementioned brain regions in vitro. However, in vivo, β-CCE inhibited the binding of [3H]Ro15-4513 in the cerebral cortex and cerebellum, but not in the hippocampus, even at an injected dose of up to 1mg/kg. In contrast, more than 50% of the in vivo binding of [3H]Ro15-1788 was inhibited by 1 mg/kg of β-CCE in all regions. The time-activity curve of [3H]Ro15-4513 in the hippocampus also showed no alteration of the peak uptake between the control group and 0.3 mg/kg of β-CCE coinjected group. These results indicated that the binding characteristics of [3H]Ro15-4513 with the BZ receptor differed markedly between the in vitro and in vivo condition, and the selectivity of [3H]Ro15-4513 binding to α5 subtype of BZ receptor in the mouse brain seemed to be remarkable under the in vivo condition.

Original languageEnglish
Pages (from-to)928-936
Number of pages9
JournalSynapse
Volume64
Issue number12
DOIs
Publication statusPublished - Dec 2010
Externally publishedYes

Fingerprint

GABA-A Receptors
Brain
Flunitrazepam
Hippocampus
Cerebral Cortex
Cerebellum
Carbolines
Ro 15-4513
Benzodiazepines
Ligands
Control Groups
In Vitro Techniques

Keywords

  • α5 subtype
  • β-CCE
  • GABA/BZ receptor
  • In vivo
  • Ro15-4513

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Remarkable selectivity of the in vivo binding of [3H]Ro15-4513 to α5 subtype of benzodiazepine receptor in the living mouse brain. / Momosaki, Sotaro; Hosoi, Rie; Abe, Koji; Inoue, Osamu.

In: Synapse, Vol. 64, No. 12, 12.2010, p. 928-936.

Research output: Contribution to journalArticle

@article{91f7a00915a9488c8b8793e9413bf6f8,
title = "Remarkable selectivity of the in vivo binding of [3H]Ro15-4513 to α5 subtype of benzodiazepine receptor in the living mouse brain",
abstract = "To evaluate the binding characteristics of [3H]Ro15-4513 with the central benzodiazepine (BZ) receptor, inhibition experiments of [3H]Ro15-1788 and [3H]Ro15-4513 were performed both in vitro and in vivo, using two BZ ligands, flunitrazepam (FNP), and ethyl-β-carboline-3-carboxylate (β-CCE). FNP inhibited the binding of [3H]Ro15-1788 and [3H]Ro15-4513 in a dose-dependent manner in the mouse cerebral cortex, hippocampus, and cerebellum, both in vitro and in vivo. β-CCE also inhibited the binding of [3H]Ro15-1788 and [3H]Ro15-4513 in all the aforementioned brain regions in vitro. However, in vivo, β-CCE inhibited the binding of [3H]Ro15-4513 in the cerebral cortex and cerebellum, but not in the hippocampus, even at an injected dose of up to 1mg/kg. In contrast, more than 50{\%} of the in vivo binding of [3H]Ro15-1788 was inhibited by 1 mg/kg of β-CCE in all regions. The time-activity curve of [3H]Ro15-4513 in the hippocampus also showed no alteration of the peak uptake between the control group and 0.3 mg/kg of β-CCE coinjected group. These results indicated that the binding characteristics of [3H]Ro15-4513 with the BZ receptor differed markedly between the in vitro and in vivo condition, and the selectivity of [3H]Ro15-4513 binding to α5 subtype of BZ receptor in the mouse brain seemed to be remarkable under the in vivo condition.",
keywords = "α5 subtype, β-CCE, GABA/BZ receptor, In vivo, Ro15-4513",
author = "Sotaro Momosaki and Rie Hosoi and Koji Abe and Osamu Inoue",
year = "2010",
month = "12",
doi = "10.1002/syn.20812",
language = "English",
volume = "64",
pages = "928--936",
journal = "Synapse",
issn = "0887-4476",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Remarkable selectivity of the in vivo binding of [3H]Ro15-4513 to α5 subtype of benzodiazepine receptor in the living mouse brain

AU - Momosaki, Sotaro

AU - Hosoi, Rie

AU - Abe, Koji

AU - Inoue, Osamu

PY - 2010/12

Y1 - 2010/12

N2 - To evaluate the binding characteristics of [3H]Ro15-4513 with the central benzodiazepine (BZ) receptor, inhibition experiments of [3H]Ro15-1788 and [3H]Ro15-4513 were performed both in vitro and in vivo, using two BZ ligands, flunitrazepam (FNP), and ethyl-β-carboline-3-carboxylate (β-CCE). FNP inhibited the binding of [3H]Ro15-1788 and [3H]Ro15-4513 in a dose-dependent manner in the mouse cerebral cortex, hippocampus, and cerebellum, both in vitro and in vivo. β-CCE also inhibited the binding of [3H]Ro15-1788 and [3H]Ro15-4513 in all the aforementioned brain regions in vitro. However, in vivo, β-CCE inhibited the binding of [3H]Ro15-4513 in the cerebral cortex and cerebellum, but not in the hippocampus, even at an injected dose of up to 1mg/kg. In contrast, more than 50% of the in vivo binding of [3H]Ro15-1788 was inhibited by 1 mg/kg of β-CCE in all regions. The time-activity curve of [3H]Ro15-4513 in the hippocampus also showed no alteration of the peak uptake between the control group and 0.3 mg/kg of β-CCE coinjected group. These results indicated that the binding characteristics of [3H]Ro15-4513 with the BZ receptor differed markedly between the in vitro and in vivo condition, and the selectivity of [3H]Ro15-4513 binding to α5 subtype of BZ receptor in the mouse brain seemed to be remarkable under the in vivo condition.

AB - To evaluate the binding characteristics of [3H]Ro15-4513 with the central benzodiazepine (BZ) receptor, inhibition experiments of [3H]Ro15-1788 and [3H]Ro15-4513 were performed both in vitro and in vivo, using two BZ ligands, flunitrazepam (FNP), and ethyl-β-carboline-3-carboxylate (β-CCE). FNP inhibited the binding of [3H]Ro15-1788 and [3H]Ro15-4513 in a dose-dependent manner in the mouse cerebral cortex, hippocampus, and cerebellum, both in vitro and in vivo. β-CCE also inhibited the binding of [3H]Ro15-1788 and [3H]Ro15-4513 in all the aforementioned brain regions in vitro. However, in vivo, β-CCE inhibited the binding of [3H]Ro15-4513 in the cerebral cortex and cerebellum, but not in the hippocampus, even at an injected dose of up to 1mg/kg. In contrast, more than 50% of the in vivo binding of [3H]Ro15-1788 was inhibited by 1 mg/kg of β-CCE in all regions. The time-activity curve of [3H]Ro15-4513 in the hippocampus also showed no alteration of the peak uptake between the control group and 0.3 mg/kg of β-CCE coinjected group. These results indicated that the binding characteristics of [3H]Ro15-4513 with the BZ receptor differed markedly between the in vitro and in vivo condition, and the selectivity of [3H]Ro15-4513 binding to α5 subtype of BZ receptor in the mouse brain seemed to be remarkable under the in vivo condition.

KW - α5 subtype

KW - β-CCE

KW - GABA/BZ receptor

KW - In vivo

KW - Ro15-4513

UR - http://www.scopus.com/inward/record.url?scp=77958161142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958161142&partnerID=8YFLogxK

U2 - 10.1002/syn.20812

DO - 10.1002/syn.20812

M3 - Article

VL - 64

SP - 928

EP - 936

JO - Synapse

JF - Synapse

SN - 0887-4476

IS - 12

ER -